Hybrid-Based Drugs Targeting Multiple Sites of Action

This is the authors' abstract. We don't add key points for this paper.

The single-target approach stays the current medication revolution in medicine for the manufacturing of new bioactive particles, there is expanding acknowledgment that this is the principal reason for an absence of a fruitful treatment for the therapy of multifactorial, complex infections like malignant cancer or Alzheimer. also, an elective methodology, commonly named the Multi-target Directed Ligand (MTDL), in light of the utilization of multifunctional is gripping the interest of in medicinal chemistry, and in the drug manufacturing organizations. The thought currently would be planning single atoms ready to interface with a few of the assorted enzymatic receptors responsible for the pathology of the infection. In this article, the benefits of these medications have been featured, and the use of these drugs in complex diseases like cancer and Alzheimer disease, acceptability of dosing regimens, increase patient compliance because it prevents multiple administrations with different bioavailability, pharmacokinetic and metabolic profiles, and what can be the future of Hybrid-based Drugs.